2025 PACUPrep BCCCP Preparatory Course Management of Secretions (Death Rattle) Therapy De-escalation, Route Conversion, and Transitional Care Planning
Therapy De-escalation, Route Conversion, and Transitional Care Planning

Therapy De-escalation, Route Conversion, and Transitional Care Planning

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

As patient goals shift toward comfort, develop protocols to taper anticholinergic infusions safely, convert from intravenous to enteral/transdermal routes, mitigate Post-ICU Syndrome, and ensure seamless discharge planning.

1. Weaning and De-escalation Protocols

When moving from life-prolonging to comfort care, anticholinergic infusions (e.g., glycopyrrolate) should be tapered gradually to prevent cholinergic rebound and minimize anticholinergic burden.

Criteria for Taper Initiation

  • Secretions are minimal and have been stable for 24 hours or more.
  • No new signs of airway obstruction or respiratory distress are present.
  • Goals of care have been formally updated to focus on comfort.

Sample Taper Scheme (Glycopyrrolate Infusion)

Sample Protocol for Tapering Glycopyrrolate Infusion
Week Infusion Rate (% of Baseline) Action
0 (Baseline) 100% Confirm secretion control and stability.
1 70% Assess every 12 hours; implement nonpharmacologic measures.
2 40% If stable, continue taper. If distress recurs, hold reduction.
3 10–20% Final taper stage; consider discontinuing infusion.

Monitoring and Adjuncts

  • Monitoring Parameters: Auscultation for oropharyngeal pooling, frequency and volume of suctioning, Respiratory Distress Observation Scale (RDOS), and patient/family comfort feedback.
  • Nonpharmacologic Adjuncts: Head-of-bed elevation, lateral positioning, gentle oral suctioning (avoiding deep suction), and clear communication with family regarding expectations.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Avoid Abrupt Cessation: A sudden stop can trigger cholinergic rebound effects such as diaphoresis, gastrointestinal upset, and a paradoxical increase in secretions.
  • Slow Taper Near End: The final reduction steps are critical. Pause any reduction if signs of distress recur to ensure patient comfort is maintained.

2. Route Conversion Strategies

Converting anticholinergics from intravenous (IV) to enteral or transdermal routes maintains symptom control with greater ease of administration, facilitating care outside the intensive care unit (ICU).

Principles of Pharmacokinetic Equivalence

  • Agents with high enteral bioavailability (e.g., glycopyrrolate) can often be converted 1:1 based on total daily dose.
  • For drugs with variable absorption, a conservative approach is to start the enteral dose at 75–80% of the total daily IV exposure and titrate as needed.
  • A transdermal scopolamine patch delivers approximately 1 mg over 72 hours and achieves steady state in about 24 hours. When converting, remove any concurrent oral scopolamine 12 hours before applying the patch to prevent toxicity.

Administration Considerations

  • Enteral Access: Use liquid formulations or crush immediate-release tablets. Never crush extended-release or specially coated medications. Flush feeding tubes with at least 20 mL of water before and after administration to prevent occlusion.
  • Transdermal Options: Apply patches to a clean, dry, hairless, and non-irritated area of skin, such as the upper chest or back. Rotate sites every 72 hours to reduce the risk of dermatitis. Monitor for systemic side effects like dry mouth, blurred vision, or urinary retention.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • When gastrointestinal absorption is unreliable (e.g., due to ileus), a transdermal patch offers steady drug delivery but has a delayed onset of action.
  • Always reconcile the IV stop time with the oral or patch start time to avoid therapeutic gaps or overlapping toxicity.

3. Mitigation of Post-ICU Syndrome (PICS)

Applying the ABCDEF bundle consistently throughout the ICU stay and into the step-down unit is crucial for reducing long-term cognitive, psychological, and functional impairments associated with PICS.

Identifying High-Risk Patients

  • Age > 65 years or preexisting cognitive impairment
  • Mechanical ventilation > 72 hours; deep or prolonged sedation
  • History of ICU delirium or multiple organ failure

The ABCDEF Bundle

This multicomponent, evidence-based strategy improves patient outcomes, including survival, and reduces delirium, mechanical ventilation time, and healthcare costs.

ABCDEF Bundle for ICU Care A flowchart illustrating the six components of the ABCDEF bundle: A for Assess Pain, B for Both Awakening and Breathing Trials, C for Choice of Sedation, D for Delirium, E for Early Mobility, and F for Family Engagement. A Assess, Prevent, & Manage Pain B Both Spontaneous Awakening & Breathing C Choice of Analgesia & Sedation D Delirium: Assess, Prevent, & Manage E Early Mobility & Exercise F Family Engagement & Empowerment
Figure 1: The ABCDEF Bundle. A multicomponent strategy to structure ICU care, reduce long-term consequences of critical illness, and humanize the patient experience.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • The ABCDEF bundle should be applied consistently from ICU admission through transition to the ward to maximize its benefits.
  • Family engagement (Part F) is not just a courtesy; it is a therapeutic intervention that has been shown to reduce delirium and support the patient’s emotional recovery.

4. Medication Reconciliation and Discharge Planning

A structured reconciliation process and interdisciplinary handoff are essential to avert medication errors, ensure continuity of care, and align the medication regimen with the capabilities of the patient and their caregivers.

Stepwise Reconciliation Process

  1. Compile: Create a single, comprehensive medication list that includes all ICU, ward, and pre-admission home medications.
  2. Reconcile: Systematically review the list to identify which therapies should be continued, tapered, converted to another route, or stopped entirely based on the current goals of care.
  3. Standardize: Use templated orders for complex schedules, such as tapers and route conversions, to minimize ambiguity.
  4. Verify: Confirm the availability and accessibility of necessary formulations (e.g., oral liquids, patches) in the community or destination facility.

Interdisciplinary Coordination and Education

  • Team Huddle: The pharmacist should review the plan with palliative care, nursing, social work, and case management to ensure all disciplines are aligned.
  • Caregiver Education: Explain the purpose, dosing schedule, side effects, and rescue measures for each medication. Demonstrate practical skills like patch application or feeding tube flushing.
  • Written Summary: Provide a clear, written summary of the medication plan, including a schedule and emergency contact information.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Pharmacist participation in discharge rounds has been shown to reduce medication discrepancies by approximately 50%.
  • Use the “teach-back” method to confirm that caregivers understand the plan and feel confident in their ability to manage the patient’s medications at home.

References

  1. Campbell NL, Boustani MA, Skopelja EN, et al. Pharmacist-driven interventions to de-escalate urinary antimuscarinic use in older adults: a feasibility study. J Am Geriatr Soc. 2022;70(7):2033–2040.
  2. Heisler M, Hamilton G, Abbott A, et al. Randomized double-blind trial of sublingual atropine vs placebo for death rattle. J Pain Symptom Manage. 2013;45(1):14–22.
  3. Kumari R, Jankovic J. An evidence-based update on anticholinergic use for drug-induced movement disorders. Mov Disord Clin Pract. 2024;11(3):289–302.
  4. Moons L, De Roo ML, Deschodt M, Oldenburger E. Death rattle: experiences and non-pharmacological management—a narrative review. Ann Palliat Med. 2024;13(1):150–161.
  5. New South Wales Therapeutic Advisory Group. Deprescribing guide for anticholinergic drugs for urinary incontinence. Sydney; 2018.
  6. Shimizu Y, Miyashita M, Morita T, et al. Care strategy for death rattle in terminally ill cancer patients: bereaved family perceptions survey. J Pain Symptom Manage. 2014;48(1):2–12.
  7. Society of Critical Care Medicine. ABCDEF Bundle. Accessed July 2025. https://www.sccm.org/Clinical-Resources/Guidelines/ABCDEF-Bundle
Previous Topic
Back to Lesson
Next Lesson